STOCKS TELEGRAPH

Tag: VRTX

  • Biotech Companies Stocks To Buy Now With 10x Growth Potential

    Biotech Companies Stocks To Buy Now With 10x Growth Potential

    The world of biotechnology is an interesting one. Many claims that we are currently living in the age of innovation and discovery. Pharmaceuticals alone have made strides unparalleled throughout human history.

    Treatments and medications for diseases that were once life-threatening are now readily available at one’s nearest dispensary. Similarly, biotech companies are increasingly working towards the development of treatments for various diseases and conditions that are prevalent across the world.

    Many are also proactively working towards the establishment of diagnostic technologies that work to optimize healthcare. For investors, taking early long positions in promising biotech stocks could result in explosive growth opportunities.

    The research process is laden with high-risk, and low certainty. However, with proper planning and foresight, one could make a fortune with the right pick.

    Here we present a list of 5 biotech companies’ stocks that could potentially drive up your portfolio by a growth factor of 10.

    What Are Biotech Stocks?

    Biotech stocks are fascinating investments that can potentially offer significant growth opportunities in the field of biotechnology.

    So, what exactly are biotech stocks? Well, think of them as companies that specialize in utilizing biological processes to develop innovative solutions in areas such as healthcare, pharmaceuticals, and agriculture.

    When it comes to biotech stocks, there are two main categories to consider: large-cap and small-cap.

    Large-Cap Biotech Stocks

    Let’s start with large-cap biotech stocks. These are the big players in the industry, with a market capitalization exceeding $10 billion. These companies have a solid track record, diverse product pipelines, and established financial stability.

    While large-cap biotech company stocks may not experience wild swings in value like their smaller counterparts, they still have the potential to deliver steady growth over time.

    Small-Cap Biotech Stocks

    On the other hand, small-cap biotech stocks refer to companies with a market capitalization below $2 billion.

    These companies are usually in the early stages of development, and their success hinges on the successful commercialization of their innovative products.

    Small-cap biotech stocks can offer significant growth potential but also involve higher risk due to their relative financial fragility.

    Top Biotech Stocks In 2023

    Top biotech stocks in 2023

    1. Axsome Therapeutics

      Axsome Therapeutics (AXSM) is a biotech gem. Their candidate, AXS-05, is nearing FDA approval for major depressive disorder.

      With the recent Sunosi acquisition and plans for ADHD trials, Axsome is poised for explosive growth. Don’t miss out on this stock’s immense potential and exciting future prospects.

    2. BioMarin Pharmaceutical

      BioMarin Pharmaceutical Inc. (BMRN) is a biotech treasure with a focus on rare, life-threatening conditions.

      Their robust pipeline includes the hemophilia treatment ValRox, close to commercialization, and the FDA-approved Voxzogo for achondroplasia. This high-growth phase could potentially multiply your portfolio several times over. Don’t miss out!

    3. Vertex Pharmaceuticals

      Vertex Pharmaceuticals Incorporated (VRTX) is a game-changer in biotech. With commercialized products for cystic fibrosis, it enjoys reduced risk and strong cash flow.

      Their diversified pipeline covers areas like pain treatment, sickle cell disease, and gene editing, ensuring explosive growth potential. Invest in Vertex for a bright biotech future.

    4. Global Blood Therapeutics

      Global Blood Therapeutics, Inc. is an innovative biopharmaceutical company that stands out in the biotech world. Despite economic conditions, GBT’s forward-thinking approach promises exponential growth.

      While their pipeline shows great promise, it’s their commercialized product, Oxbryta, that impresses. With $375 million in sales and EU approval for younger patients, GBT’s revenue could skyrocket.

      Investing in GBT now could lead to substantial capital gains in the future.

    5. SIGA Technologies

      SIGA Technologies (SIGA) is another biotech gem with a focus on infectious diseases. Their FDA-approved product, T-poxx, treats monkeypox and holds tremendous growth potential.

      With government support and widespread vaccination efforts, investing in SIGA now could lead to handsome returns as the disease spreads. Don’t miss out on this strategic opportunity.

    6. Recursion Pharmaceuticals

      Recursion Pharmaceuticals (RXRX) stands out as a top investment choice. Their AI-driven drug discovery platform, strong financials, and diverse pipeline differentiate them from rivals like AstraZeneca, Novartis, Roche, and Biogen.

      With a remarkable 128% YoY revenue growth in Q1 2023 and strategic acquisitions, Recursion leads the way in unparalleled drug discovery.

    7. Arrowhead Pharmaceuticals

      Arrowhead Pharmaceuticals Inc. (ARWR) is a great biotech stock! With its robust platform and diverse drug pipeline, they’re taking on a range of diseases—from the liver to cardiovascular, pulmonary, and even central nervous system ailments.

      The team behind Arrowhead is an impressive bunch, combining expertise with a burning passion. Investing in them promises rewarding returns for your biotech/pharma portfolio.

    8. BeiGene Ltd.

      Let’s talk about BeiGene Ltd. (BGNE), a biotech powerhouse focused on oncology treatments. They had a solid Q1 2023, but face a patent lawsuit from AbbVie.

      Despite the challenge, BGNE’s diverse drug portfolio, strong R&D, and momentum make it a hold for existing shareholders. Potential investors should monitor the lawsuit and profitability. Stay informed, and invest wisely!

    9. MaxCyte

      MaxCyte Inc. (MXCT) is a game-changer in the world of biotech. Their cutting-edge cellular engineering platform opens up a world of possibilities in areas like cell-based therapies, gene editing, and drug discovery.

      With a backlog of over $1.55 billion in milestones and the potential for long-term royalties, investing in MaxCyte seems like a smart move.

      This innovative firm has the potential to revolutionize the biotech industry and deliver substantial returns for investors.

    10. FibroGen

      FibroGen, Inc. (FGEN) is an exciting investment prospect with imminent phase 3 study results for treating Duchenne Muscular Dystrophy.

      With a projected $2.1 billion market opportunity by 2031 and upcoming findings for idiopathic pulmonary fibrosis, this biotech stock holds significant growth potential. Stay tuned for remarkable developments!

    11. Precigen

      Despite financial setbacks, Precigen Inc. (PGEN) shines in its clinical programs. PRGN-2012 shows promise in treating respiratory papillomatosis, with a remarkable 50% complete response rate in severe cases after 12 months.

      A ‘buy’ for investors with a high-risk tolerance and a long-term perspective on the transformative gene and cell therapy potential.

    12. Pyxis Oncology

      Looking for a high-growth biotech stock? Check out Pyxis Oncology (PYXS). Their phase 1 studies on PYX-201 (anti-EDB ADC) and PYX-106 (anti-Siglec-15 drug) target various cancers.

      Excitingly, results are expected in late 2023 and early 2024. Plus, the company’s cash reserves can support operations until 1H 2025. A promising speculative play!

    13. Krystal Biotech

      Krystal Biotech, Inc. (KRYS) is a thrilling gem in the world of gene therapy. Their flagship product, B-vec, brings hope to those battling dystrophic epidermolysis bullosa, a distressing skin condition.

      While the market for B-vec may be modest, Krystal Biotech’s broader portfolio includes KB407, a gene therapy for cystic fibrosis with immense potential. Investing in KRYS means supporting cutting-edge innovation with vast market opportunities.

    14. Werewolf Therapeutics

      Werewolf Therapeutics, Inc. (HOWL) is an exciting biotech stock with immense potential. They’re close to revealing data from WTX-124’s phase 1 trial, and a partnership with JAZZ might trigger a milestone.

      Though WTX-330’s data might be delayed until H1’24, HOWL’s cash runway is solid until at least Q4’24. Invest in HOWL for promising growth.

    15. Cabaletta Bio

      Cabaletta Bio (CABA) is an exciting biotech play. With IND clearance for a lupus study and upcoming results for pemphigus vulgaris and myasthenia gravis trials, investing in CABA means betting on innovation and potential growth in a $3.6 billion market.

    16. Apellis Pharmaceuticals

      Apellis Pharmaceuticals (APLS) is a biotech gem. Its C3 inhibitor, pegcetacoplan (Syfovre), impresses with positive Phase III trials for PNH and GA.

      Q1 2023 sales surpassed expectations, and with a solid cash balance of $765.1 million, Apellis is set for growth. A speculative buy with a differentiated pipeline.

    17. PDS Biotechnology

      PDS Biotechnology (PDSB) is an exciting biotech stock to consider. Their upcoming phase 3 study using PDS0101 and Keytruda for head and neck cancer, along with the projected $6.2 billion market by 2029, make it promising.

      They’ve also licensed PDS0301 from Merck KGaA. Keep an eye on PDSB as they may need to raise additional funds.

    18. Poseida Therapeutics

      Poseida Therapeutics (PSTX) is an exciting biotech stock with high-growth potential. Phase 1 study results for P-MUC1C-ALLO1 and P-BCMA-ALLO1 are due in 2023.

      A partnership with Roche could bring up to $6 billion in milestone payments. Keep an eye out for their upcoming IND filing and gene therapy candidates. Don’t miss out on this opportunity!

    19. Ardelyx

      Consider investing in Ardelyx (ARDX), a promising speculative biotech. Watch out for their May 2023 earnings release to gauge ibsrela sales growth.

      With the global irritable bowel syndrome market set to reach $2.01 billion by 2026, Ardelyx holds significant potential. The FDA’s acceptance of XPHOZAH’s NDA and an upcoming review by mid-May 2023 hint at exciting prospects.

      Expect the commercial launch of XPHOZAH in the second half of 2023.

    20. argenx SE

      argenx SE (ARGX) impresses with $218M Q1 Vyvgart revenue, but risks arise from the CIDP ADHERE trial’s historically high placebo responses and limitations.

      The frothy valuation and clinical development risks warrant caution. We maintain a hold rating due to uncertainties and an inflated $21Bn valuation, though we believe in argenx’s long-term potential.

    21. Amylyx Pharmaceuticals

      Amylyx Pharmaceuticals (AMLX) is a biotech name that shines bright amidst uncertainties. Relyvrio, their ALS treatment, raked in $71.4M in Q1 2023, fueling projections of over $1B annual revenue.

      A 9% share price drop signals undervaluation, upgrading it to a definite “Buy.” Brace for fluctuations and regulatory discussions until late 2024.

    22. NewAmsterdam Pharma

      NewAmsterdam Pharma is a hidden gem in the biotech world. With their focus on cardiovascular diseases, they’ve developed a game-changer called Obicetrapib.

      This promising drug has demonstrated remarkable potential in lowering LDL-C and apoB levels. As Phase III trials progress, we anticipate further validation of its unique qualities, boosting investor trust and propelling the stock price.

      NewAmsterdam Pharma has a resounding buy rating.

    23. Astria Therapeutics

      Astria Therapeutics (ATXS) is a promising biotech stock. Their STAR-0215 shows potential as a preventative Hereditary Angioedema therapy. Anticipate phase 1b/2 ALPHA-STAR study results in mid-2024.

      The global HAE market could reach $6.5 billion by 2025. Astria has $226.4 million in cash, sustaining operations until H1 2025. ATXS is an exciting investment opportunity.

    24. Legend Biotech Corporation

      Legend Biotech Corporation (LEGN) is an exciting investment choice.

      Carvykti’s impressive performance in the CARTITUDE-4 trial, with a hazard ratio of 0.26 and no safety concerns, along with J&J’s $72 million net sales, positions LEGN to capture a significant market share in multiple myeloma. A compelling opportunity indeed.

    25. Equillium

      Equillium Inc. (EQ) is an exciting biotech stock. They secured a lucrative deal with Ono Pharmaceutical for Itolizumab rights, and now focus on two promising multi-cytokine inhibitor programs.

      Analysts undervalue these programs, offering significant upside potential. Even if the programs fail, the cash and Ono deal provides a 2X upside. It’s a compelling investment opportunity.

    26. Omeros Corporation

      Omeros Corporation (OMER) shows great promise for investors.

      With upcoming milestones like the BLA resubmission for narsoplimab and the IgAN trial results, coupled with solid financials and an attractive risk/reward balance, Omeros is an exciting biotech stock worth considering for high-growth potential.

    27. Achieve Life Sciences

      Achieve Life Sciences (ACHV) is a biotech gem. With stellar Phase 2 results for cytisinicline in helping users quit vaping, it’s up 200%+ this year. Safe and potentially FDA-approved, upcoming Phase 3 outcomes make it a stock to watch. Just be mindful of cash and regulatory risks, and the need for a pharma partnership.

    28. Hookipa Pharma

      Hookipa Pharma Inc. (HOOK) is an exciting biotech stock. Their platform uses arenaviruses to stimulate the immune system against infectious diseases and cancer.

      With partnerships including Gilead, Merck, and Roche, HOOK has huge growth potential. Trading at a discount and with a negative enterprise value, it’s a worthy addition to my watchlist.

    29. Geron

      Geron Corporation (GERN) shines as a high-growth biotech stock. Their drug Imetelstat delivers impressive results for lower-risk myelodysplastic syndromes (LR-MDS). FDA approval, priority review, and a launch in H1 2024 are on the horizon.

      GERN’s differentiator? It excels in heavily transfusion-dependent patients, setting it apart from competitors. Invest with confidence!

    30. Gilead Sciences

      Gilead Sciences Inc. (GILD) is a worthwhile investment. Even without growth, it’s priced at a bigger discount than AbbVie or Amgen.

      You don’t have to guess about growth; it’s all extra. With the lowest debt cost, beta, and equity cost, Gilead offers relative safety for investors.

    31. AquaBounty

      AquaBounty (AQB) is a biotech company in aquaculture with big ambitions. It aims to genetically engineer protein and feed the world, by pioneering in the science of aquaculture.

      Despite challenges in the current economic climate, its increasing product revenue and planned production capacity show promising growth potential, even though it’s still small compared to industry giants.

    32. Royalty Pharma

      Royalty Pharma (RPRX) is worth investing in because it acquires drug royalties, with cash receipts expected to reach $3B this year.

      The company has a clear asset allocation strategy and strong projected cash flow. For capital gains, consider buying the stock; for income, go for the 5%+ yielding debt.

    33. Eli Lily

      Investing in Eli Lilly (LLY) is a no-brainer despite its seemingly disproportionate market cap. The key lies in its groundbreaking drug, Tirzepatide, which has the potential to revolutionize diabetes and weight loss treatment.

      With impressive clinical trial results and a massive market opportunity in both diabetes and obesity, Lilly’s Tirzepatide could become a trillion-dollar phenomenon. Investors are flocking to Lilly for good reason – this stock is poised for tremendous growth.

    34. Taro Pharmaceutical

      Taro Pharmaceutical Industries (TARO) received a $38 per share acquisition offer from Sun Pharma, its largest shareholder. This presents a buying opportunity as TARO has seen value erosion.

      The deal suggests undervaluation, the potential for competing bids, and an attractive exit point for investors. Invest in TARO to avail this brilliant opportunity.

    35. Verona Pharma

      Verona Pharma (VRNA) offers an exciting investment opportunity in biotech. Their groundbreaking compound, ensifentrine, targets COPD, a life-threatening lung disease.

      With promising results from ENHANCE trials and potential revenue in the global COPD market, Verona Pharma shows significant growth potential.

      Despite risks, a ‘Buy’ rating is recommended, while closely monitoring future trials for a better understanding of ensifentrine’s value.

    Investing In Gene-Editing Stocks

    Investing in the top gene-editing stocks is an exciting opportunity that merges science and finance. Imagine unraveling our genetic code to tackle diseases at their core.

    Investing in Gene-Editing Stocks

    Gene editing, with technologies like CRISPR-Cas9, promises revolutionary medical breakthroughs.

    Investing here means betting on personalized medicine, where genetic diseases are cured and human potential soars.

    The leading biotech companies attract top talent and secure valuable partnerships, fueling growth and returns.

    If you seek an investment combining cutting-edge science and profit potential, gene-editing stocks deserve attention.

    It’s a chance to be part of a transformative journey and make a meaningful impact.

    Top Gene Editing Stocks to Buy In 2023

    Listed below are the twenty top gene-editing stocks to buy in 2023:

    1. CRISPR Therapeutics AG (CRSP)
    2. Editas Medicine, Inc. (EDIT)
    3. Intellia Therapeutics, Inc. (NTLA)
    4. Beam Therapeutics Inc. (BEAM)
    5. Caribou Biosciences, Inc. (CRBU)
    6. Twist Bioscience Corporation (TWST)
    7. Graphite Bio, Inc. (GRPH)
    8. Adaptive Biotechnologies Corporation (ADPT)
    9. Ginkgo Bioworks Holdings, Inc. (DNA)
    10. Verve Therapeutics, Inc. (VERV)
    11. Vertex Pharmaceuticals Inc. (VRTX)
    12. AbbVie Inc. (ABBV)
    13. Agilent Technologies, Inc. (A)
    14. Sangamo Therapeutics, Inc. (SGMO)
    15. Fate Therapeutics, Inc. (FATE)
    16. Regenxbio Inc. (RGNX)
    17. ProQR Therapeutics NV (PRQR)
    18. Astellas Pharma Inc.
    19. uniQure N.V. (QURE)
    20. Cellect Biotechnology Ltd.

    Understanding The Biotech Industry

    Investing in the biotech industry is like venturing into a world of limitless possibilities. Picture this: scientists and researchers toiling away in laboratories, fueled by an insatiable curiosity to cure diseases and transform lives.

    Understanding the biotech industry

    Biotech companies are at the forefront of groundbreaking innovations, developing therapies that were once deemed impossible. It’s a field where science meets business, and the potential for growth is staggering.

    From gene editing to precision medicine, the biotech industry holds the key to addressing unmet medical needs and revolutionizing healthcare.

    As an investor, being part of this journey means supporting life-changing advancements while reaping the rewards of high-growth potential.

    So buckle up, because the biotech industry is poised to make incredible strides, and your investments can be the catalyst for a healthier future.

    Pros and Cons of Investing in Biotech Stocks

    Discussed below are the pros and cons of investing in biotech stocks:

    Pros Cons
    Exciting Innovation:

    Investing in biotech stocks lets you be part of groundbreaking advancements in medicine, supporting life-changing therapies and cutting-edge technologies.

    		 Volatility:

    Biotech stocks can be highly volatile due to regulatory hurdles, clinical trial outcomes, and market sentiment, which may unsettle risk-averse investors.
    High Growth Potential:

    Biotech stocks offer significant returns through rapid growth, driven by successful drug approvals, partnerships, and clinical trial results.

    		 Regulatory Risks:

    Lengthy approval processes and stringent safety standards pose challenges, and setbacks in clinical trials or approvals can significantly impact stock performance.
    Diversification:

    Including biotech stocks in your portfolio enhances diversification by adding exposure to a unique and dynamic industry, potentially reducing overall portfolio risk and providing a hedge against other sectors.

    		 High Failure Rates:

    Biotech research and development carry inherent risks, as many drug candidates fail to achieve regulatory approval or commercial success. Careful assessment of a company’s pipeline and prospects is crucial to mitigate the risk of investing in unsuccessful ventures.

    How To Buy Biotech Stocks

    So you’re interested in investing in the exciting world of biotech? Great choice! Biotech stocks offer incredible growth potential, fueled by groundbreaking innovations that can revolutionize healthcare. It is important to know where to buy biotech stocks from before you proceed.

    Let’s explore two approaches to consider:

    • Individual Biotech Stocks

      Investing in individual biotech stocks allows you to handpick companies with promising breakthroughs. It’s like being part of their journey, cheering for their success, and reaping the rewards if they hit the jackpot. It’s thrilling and potentially profitable!

    • Biotech Stock ETFs

      For those seeking a more diversified approach, biotech stock ETFs are the way to go. These funds pool together a collection of biotech companies, spreading the risk while capturing the industry’s overall growth potential.

      It’s like having a basket filled with high-potential stocks, minimizing the impact of any single company’s performance. A smart move for long-term investors!

    Risks of Biotech Stocks

    Investing in biotech stocks can carry a certain level of risk, as with any investment in the stock market. The biotech industry is highly dynamic and subject to various factors that can impact stock prices.

    Market volatility, regulatory hurdles, clinical trial outcomes, competition, and broader market uncertainties are some of the general risks that investors may encounter.

    However, it’s important to note that risk and potential reward often go hand in hand. Biotech stocks also offer the potential for substantial growth and the opportunity to be part of groundbreaking scientific advancements.

    Investors should carefully assess their risk tolerance, conduct thorough research, and diversify their portfolios to make informed investment decisions in the biotech sector.

    Conclusion

    The biotech industry is typically perceived as being one that is highly rewarding, yet, laden with significant risk.

    Even in the case where testing goes positively, there is no guarantee as to whether or not a profit will be turned.

    For this reason, it is crucial for investors to remain strategic in their analyses, and identify which stocks hold the lowest risk and highest growth potential.

    Each of the stocks mentioned would ensure you stand exposed to the explosive growth opportunities that the innovative biotech industry is likely to achieve.

    Frequently Asked Questions

    Why Other Stocks Didn’t Make the Cut

    Other stocks didn’t make the cut because they lacked the growth potential and transformative impact that biotech stocks offer. Investing in biotech means being part of a scientific revolution that can shape the future of healthcare.

    Is The Golden Age of Biotech Stocks Over?

    No, the golden age of biotech stocks is far from over! With breakthrough innovations, expanding global healthcare needs, and the potential for life-changing treatments, the biotech sector continues to offer exciting investment opportunities.

  • 7 Biotech Stocks to Buy in 2021

    7 Biotech Stocks to Buy in 2021

    Change is inevitable in every aspect of life because it results from human exploration and applying knowledge to improve life quality. This is why many industries have shown significant growth with time, and the biotech industry is one of them. The biotech industry has extraordinarily impacted healthcare, biological science, economy, and business in recent years. The plethora of biotech stocks continuously put their efforts into developing therapeutics and vaccines that are effective and less toxic, and easily accessible for individuals. With the rise of COVID-19, the Biotech industry has gained more importance. Many biotech stocks have developed and commercialize vaccines in the battle against the deadly pandemic. Now many investors are looking for biotech stocks to get high profits in the future. Here are the 7 biotech stocks to buy in 2021.

    Pfizer (PFE)

    The first and foremost stock to watch in 2021 is Pfizer (PFE), one of the first biotech stocks to market the COVID-19 vaccine. Since then, it has contracted with many governments and supplied millions of doses and looking forward to providing more than this in the future. The U.S government has a plan to vaccinate all of its adult population, and Pfizer is likely to contribute a lot to this cause. While many other biotech stocks only focus on older patients, Pfizer is also developing a COVID-19 vaccine for children, which is another positive sign for future growth. The company has a market cap of more than $220 billion and annual revenue of more than $40 billion. Hence Pfizer stock can be a good bet in 2021. 

    Regeneron Pharmaceuticals (REGN)

    The second stock that could prove fruitful for investors in 2021 is Regeneron Pharmaceuticals(REGN). The company has a market cap of more than $55 billion and is engaged in discovering, developing, and manufacturing various therapeutics to treat medical conditions worldwide. One of the two authorized antibody treatments to treat COVID patients belongs to Regeneron. Its recent first-quarter results show that its quarterly revenue showed 38% growth year over year. Its COVID-19 antibody treatment alone generated $262 million in the first quarter of 2021. Besides this, Eylea, a drug to treat eye diseases, also impacts its increased sales over time. Hereafter, investors need to keep an eye on this stock.

    Novavax (NVAX)

    On Number three, we have Novavax (NVAX). It is another biotech stock engaged in the development of commercialization of vaccines to prevent infectious diseases. Novavax has significantly outperformed in the COVID-19 era and still giving a tough time to its competitors. Its COVID-19 vaccine candidate NVX-CoV2373 could bring massive profits in the future. Novavax is about to finalize the major supply deal with the European Union, which means the supply of 500 million or more doses. So, a lot of money on the line is expected for Novavax stock. 

    Moreover, it has also inked supply deals with many countries in which India is also included, which has more than 1.3 billion population. Novavax generated a breathtaking $447 million in revenue in the first quarter of 2021 compared to $3 million in the same quarter of last year. This significantly increased revenue shows its success over the year. In a nutshell, investors should keep an eye on this stock.

    Bio N Tech SE (BNTX)

    On Number four, we have Bio N Tech (BNTX), which is a biotechnology company engaged in discovering and developing therapeutics to treat various infectious diseases. Bio N Tech is the partner of Pfizer in the battle against COVID-19. BNTX stock expects $26 billion in sales for the COVID-19 vaccine and its partner in 2021 and estimates roughly $3 billion in earnings. Millions of the mutually prepared COVID-19 vaccine doses have been delivered to many countries so far. Both partners are negotiating with many other countries to supply COVID-19 vaccine doses worth $3 billion by 2022, which points to the bright future of BioNTech stock. So it can be a good bet for investors in the future.

    Ocugen (OCGN)

    Ocugen (OCGN), stands at number five on our list. It is a clinical-stage biopharmaceutical company focused on developing therapeutics to cure blindness and other retinal diseases. Ocugen stock is working with Bharat Biotech to develop COVAXIN and the vaccine used to treat COVID patients. The phase-3 study results of COVIXIN showed 100% efficacy against severe coronavirus and 78% efficacy against mild and moderate COVID-19 disease. The Indian government has given emergency use authorization to Bharat Biotech which is a positive sign for Ocugen stock. Ocugen stock is looking forward to developing the COVID-19 vaccine for other markets and can be a good bet for investors in the future.

    Seagen (SGEN) 

    Seagen Inc is an American-based biotech stock focused on developing and commercializing therapeutics to treat cancer patients, and it’s in the Number six position on our list. Seagen has shown significant growth in 2020 as compared to 2019. Its revenue for 2020 totaled $2.2 billion, which shows 140% growth over the year. The revenue for the year 2019 was $916.7 billion. The company has achieved global success with Adcetris, an antibody medicine used to treat lymphoma, and is in an excellent position to invest more in developing newer medications. Therefore, Seagen is one of the biotech stocks to watch in 2021.

    Vertex Pharmaceuticals (VRTX)

    The seventh biotech stock to watch in 2021 is Vertex Pharmaceuticals Incorporated (VRTX), which is mainly focused on developing and commercializing therapeutics to treat cystic fibrosis. Trikafta is the most important drug of Vertex pharmaceutical that treats roughly 90% of patients with cystic fibrosis. Estimates show that 70,000 cystic fibrosis patients are there globally, and Trikafta is the only medication available for this disease. Vertex stock has generated significant revenue through Trikafta and some other products, which will continue to rise in the future. The company has partnered with CRISPR Therapeutics and announced impressive results from a clinical trial of gene therapy for two rare blood diseases. Consequently, its continued success against cystic fibrosis and clinical developments suggests that this stock could outperform in the long run.

    The following three biotech stocks are with the lowest 12-month trailing price-to-earnings ‎ratio (P/E). Dividends and buybacks are two ways a company can return profits to ‎shareholders, so a low P/E ratio shows you are paying less for every dollar of profits ‎generated.

    The Agios Pharmaceuticals (AGIO)‎

    The Agios Pharmaceuticals Inc. platform is a pharmaceutical company dedicated to ‎developing drugs for genetic diseases such as hemolytic anemias and sickle cell disease. In Q1 ‎‎2021, the company reported a net income of $1.9 billion, a far cry from its Q1 2020 loss. ‎Agios’ oncology portfolio was sold to Servier Pharmaceuticals LLC in the first quarter, which ‎had an impact on revenue.

    Sage Therapeutics, Inc.. (SAGE)

    Sage Therapeutics has developed treatment for issues related the central nervous system, including schizophrenia and major depression. The company reported positive results from its SAGE-718 clinical trial, a drug that may be used to treat Huntington disease, in Q1 2021.

    Innoviva Inc. (INVA)

    Innoviva is a healthcare-oriented asset manager that holds portfolios of royalties for many pharmaceuticals.

  • Early Morning Vibes: 4 Top Trending Stocks To Watch Right Now

    Early Morning Vibes: 4 Top Trending Stocks To Watch Right Now

    US stock exchanges fell on Monday in line with the overall decline in risk sentiment in global markets, according to trading data.

    The Dow Jones Industrial Average (DJIA) fell by 0.33% to 31391.89 points, the NASDAQ high-tech index – by 0.86% to 13756.78 points, the broad market S&P 500 index – by 0.47%, up to 3887.8 points.

    Monday traders are risk averse. Their attention turned to the possible consequences of the economic recovery after the pandemic. In particular, investors are concerned that the US $1.9 trillion stimulus package will lead to increased economic activity and a surge in inflation, which in turn could prompt the Fed to tighten monetary policy.

    At preliminary trades, the pressure on the share price was also exerted by the growth of the yield on US government bonds to the maximum since February last year, which contributed to the strengthening of the dollar. However, the yield on government bonds has already moved to a correctional decline. The dollar is also slightly declining.

    Meanwhile, the shares of the American concern Boeing are losing 1.8% after the company recommended to suspend flights of 777 liners with a Pratt & Whitney PW4000-112 engine amid an emergency with an engine in Colorado.

    Today Top Movers‎

    ReTo Eco-Solutions Inc. (NASDAQ: RETO) shares are trading up 36.75% at $3.2 at the time of writing.

    Vascular Biogenics Ltd (VBLT) jumper over 58.30% at $3.53 in pre-market trading today after declaring results of the independent Data Safety Monitoring Committee pre-planned review of the ongoing OVAL Phase 3 registration enabling study of VB-111 in recurrent ovarian cancer. ‎

    TFF Pharmaceuticals Inc. (TFFP) stock soared 10.2% to $17.5 in the pre-market ‎trading.

    Celsion Corporation (CLSN), a biotechnology company, dropped about -22.42% at $2.18 in pre-market trading Tuesday after receiving FDA fast track designation for GEN-1 in Advanced Ovarian Cancer.‎ ‎

    Top Upgrades & Downgrades

    KeyBanc turned bullish on iQIYI Inc. (IQ), upgrading the stock to “Overweight” and assigning a $30.0 price target, representing a potential upside of 25.63% from Monday’s close. 

    TimkenSteel Corporation (TMST) has won the favor of KeyBanc’s equity research team. The firm upgraded the shares from Sector Weight to Overweight and moved their price target to $10.0, suggesting 58.98% additional upside for the stock. 

    Vertex Pharmaceuticals Incorporated (VRTX) received an upgrade from analysts at Baird, who also set their one-year price target on the stock to $252. They changed their rating on VRTX to Outperform from Neutral in a recently issued research note.

    Earlier Tuesday Jefferies reduced its rating on GasLog Ltd. (GLOG) stock to Hold from Buy and assigned the price target to $5.8. 

    Evercore ISI analysts reduced their investment ratings, saying in research reports covered by the media that its rating for Principal Financial Group Inc. (PFG) has been changed to In Line from Outperform and the new price target is set at $63. 

    Analysts at Societe Generale downgraded DISH Network Corporation (DISH)’s stock to Sell from Hold Tuesday.

    Latest Insider Activity

    Pinterest Inc. (PINS) Director Levine Jeremy S. announced the sale of shares taking place on Feb 19 at $86.47 for some 150,000 shares. The total came to more than $12.97 million. 

    Coeur Mining Inc. (CDE) SVP, Exploration Rasmussen Hans John sold on Feb 22 a total 309,185 shares at $8.91 on average. The insider’s sale generated proceeds of almost $32967. 

    SLM Corporation (SLM) Director Franke Mary Carter Warren declared the purchase of shares taking place on Feb 17 at $15.03 for some 7,000 shares. The transaction amount was around $0.11 million. 

    Corvus Pharmaceuticals Inc. (CRVS) President and CEO MILLER RICHARD A MD bought on Feb 17 a total 1,278,515 shares at $3.50 on average. The purchase cost the insider an estimated $350,000.

    Important Earnings

    Top US earnings releases scheduled for today include Macy’s Inc. (NYSE: M). It will announce its Jan 2021 financial results. The company is expected to report earnings of $0.12 per share from revenues of $6.5B in the three-month period. 

    Analysts expect Square, Inc. (SQ) to report a net income (adjusted) of $0.24 per share when the company releases its quarterly results shortly. Revenue for the fiscal quarter ended Dec 2020 is predicted to come in at $3.09B. 

    B2Gold Corp. (BTG), due to announce earnings after the market closes today, is expected to report earnings of $0.01 per share from revenues of $207.75M recently concluded three-month period.

  • The Three Top Healthcare Stocks to Buy in 2021

    The Three Top Healthcare Stocks to Buy in 2021

    The healthcare sector is a massive industry with a wide potential for investors.

    Healthcare is a basic necessity for people all over the world. Each year, we see new types of mysterious diseases that are often deadly. Such as the coronavirus is one of the broad examples of it. The global pandemic has caused more than 2.3 million deaths, and almost 107 million are facing the virus.

    Despite the health concerns, many of the health stocks made big gains. However, healthcare stocks as a whole underperformed the broader market, rising 11% compared to S&P 500 rose 15.9%. Still, the sentiment regarding healthcare stocks is high with the public health concerns. The vaccine is still in a frantic zone and many companies are still researching for more improvement.

    In that premise, healthcare is a big market and has massive potential. So, let’s have a look at the three top healthcare stocks to buy this year.

    Medtronic (MDT)

    Medtronic (MDT) is an American Irish-domiciled medical device corporation. The company generates most of its sales and profits from the US healthcare market. The healthcare firm with nearly $159 billion market value is a compelling stock for investors. Medtronic is among healthcare firms with safe, stable, and longer-term growth potential.

    Talking about Medtronic’s stability, the company is an exclusive member of the S&P dividend aristocrats list. This means that MDT is those dividend stocks that have raised their dividend payments for a consecutive 25 years long period or more. While MDT has an undisputed streak of over 43 years. 

    Medtronic has shown interest in investing in Compute Health Acquisition Corp., a blank-check company that is expected to go public—with an IPO of $750 million. The company has plans to buy almost 1.5 million units in the offering.

    Compute Health has plans to invest in the healthcare sector through the rising computing power and AI technology. This biotech healthcare is set to change the dynamics of the healthcare industry. So, Medtronic’s potential investment could be an effective one in the long-term.

    Vertex Pharmaceuticals (VRTX)

    Vertex Pharmaceuticals (VRTX) is one of the leading in the healthcare industry. The company’s primary focus remains on the development of drugs that treat the basic cause of cystic fibrosis (CF). CF is a rare genetic disease that causes lung problems and damages other organs, as well.

    The company’s most prominent drug, a 3-in-1 pill – Trikafta that obtain approval back in 2019, generated over $3.9 billion in sales for the very first year in 2020. Trikafta is anticipated to drive the company’s revenue for the next few years.

    Furthermore, Vertex’s management has indicated acquiring more assets to diversify its portfolio and accelerate its pipeline. VRTX shares are down and are expected to have an upward movement anytime soon. So, it’s one of the stocks to buy with potential upside.

    McKesson Corp. (MCK)

    McKesson Corp. (MCK) is a pharmaceutical and other healthcare products supplier and distributor. McKesson is more of a logistics firm, still, its involvement in the healthcare sector makes it a promising healthcare firm.

    The company recently reported third-quarter FY21 results which came on top with the rise in distribution services. The adjusted gross profit soared over 7% year-over-year, which was mostly driven by an incline in the distribution of COVID-19 tests. Moreover, McKesson’s work assembling ancillary supply kits for COVID-19 vaccines also played a key role in profit growth.

    The company distributed over 25 million vaccine doses of Moderna’s COVID-19 vaccine in January. The pharmaceutical distributor expects more contracts to be signed with the U.S. government for the distribution of more vaccines.   

    With this, the company has upgraded its full-year 2020 outlook and anticipates the adjusted earnings between $16.95 and $17.25 per share. So, McKesson Corp. (MCK) seems a suitable investment option with potential growth opportunity this year.

  • 3 of the Best Biotech Stocks to Buy for 2021

    3 of the Best Biotech Stocks to Buy for 2021

    Due to the spread of the coronavirus pandemic all over the world Biotech stocks have gained great attention in the market. There is great competition between biotech giants, and this makes investors confuse to predict which stock will be more fruitful for them in terms of revenue. But one should not ignore the fact that other diseases and medical challenges still exist even if they are not like that much popular as the COVID-19 is.

    Moderna Inc (NASDAQ: MRNA)

    Moderna, Inc. (MRNA) is a leading mRNA Technology platform that aims on using messenger RNA (mRNA) to produce a new generation of transformative drugs for patients.

    2020 proved to be a good year for Moderna because its share price has reached up to the mark of more than 500%.Covid-19 mRNA-1273 is mainly responsible for this rise as this vaccine has shown very effective results. Further this vaccine has gained the trust of about 30 countries’ regulatory bodies as they have approved it for use.

    According to MichaelYee, a Wall Street analyst, Moderna has already signed $11.7B in contracts in which dose range is from 510M to 525M. The company is looking forward to signing additional contracts for 2021 and 2022 where the capacity will reach up to 1.2B doses.

    Moderna has to compete with its competitors especially Pfizer and JNJ(which is going to share results 3rd trial phase of Covid-19 Vaccine shortly) to maintain its reputation but due to the very high demand for vaccine in the globe, at least five companies can sell at full capacity to fulfill the need of vaccine in the globe. Moderna has also stepped in the 2nd phase study of the age group from 12 to 17 and U.S. Food and Drug may authorize vaccine for teens which could add more value to Moderna’sannual revenue.

    Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)

    Vertex Pharmaceutics Inc.(VRTX) is focused on discovering, developing & manufacturing small molecule drugs for the cure of cystic fibrosis, viral infections, bacterial infections, autoimmune diseases, cancer, and neurological disorders.

    The company is playing the lead role in the cure of cystic fibrosis as it is estimated that 50% of patients diagnosed with cystic fibrosis in many countries are using Vertex’s medications. Vertex’s main product is Trikafta which is approved by the FDA at the end of 2019. Trikafta has already generated $3b revenue alone and is expected to generate more in the future as the company is putting serious effort to get the approval of this product for different age groups.

    Novavax, Inc. (NASDAQ: NVAX)

    Novavax, Inc. (NVAX) is a late-stage company that aims in improved global health through the discovery, development, and commercialization of innovative vaccines to prevent infectious disease. The company’s main contributions in preventing diseases include COVID-19, seasonal influenza, RSV, Ebola, Mers, and SARS.

    The company has recently announced that it has contracted with the Government of Canada to supply 76Million doses of NVX-CoV2373, a company’s recombinant protein-based COVID-19 vaccine, to control the pandemic in the region. This contract will help the company to generate a handsome revenue in future.

    Besides the COVID-19 vaccine, the company is putting some serious effort into Nanoflu, a seasonal influenza vaccine for the olders, to influence the global influenza market which will worth more than 6Billion annually by 2026. The 3rd clinical analysis of the Nanoflu showed exceptional results and now the company is expecting to get approval from the U.S food and drug administration soon to commercialize its product and if it happens, it will further boost the company’s reputation and maximize the potential to generate billions of dollars revenue annually.

  • Early Morning Vibes: Top 4 Stocks Trending on Wednesday

    On December 29, the American stock indices closed in the red. The S&P 500 at the beginning of the session renewed its all-time high, but by its close it dropped 0.22% to 3727 points, the Dow Jones also lost 0.22%, the NASDAQ fell 0.38%. The news background remained calm, but investors preferred to fix some of their positions. The healthcare sector took the lead in growth with a result of + 0.44%, while the real estate sector corrected by 0.71%.

    Company news

    Fulgent Genetics (FLGT: + 8.7%) will provide COVID-19 diagnostic tests to New York City students and educational workers.

    Activist investor Third Point sent a letter to Intel management (INTC: + 4.9%) urging them to consider changes to the company’s strategy.

    Arcturus Therapeutics (ARCT: -54.2%) has published the results of the first phase of clinical trials of a COVID-19 vaccine, which turned out to be weak.

    Today, world stock exchanges are showing mostly positive dynamics. Investors are focusing on the prospects for increasing the volume of direct payments to Americans. Senate Majority Leader Mitch McConnell has blocked an attempt to vote on raising the benefit from $ 600 to $ 2,000, so the timing of the discussion remains uncertain. A number of Republicans do not support the president’s initiative to increase the lump sum, pointing to the problem of the budget deficit and high public debt, which hinders the increase in government spending. In the meantime, Americans will start receiving checks for $ 600 today as part of the previously approved economic stimulus program.
     

    On the front of the fight against COVID-19 in the United States, there is no significant positive so far. Colorado has recorded the first patient with a British modification of the coronavirus. The increase in incidence has slowed slightly, but a new outbreak is forecast after the holidays. The number of hospitalized in the United States already exceeds 124 thousand, and the trend remains negative. The vaccination campaign is very slow: so far only 2.13 million have been vaccinated. As Joseph Biden noted, if the process is not accelerated, it may take years, not months, to complete vaccination. This is a significant risk for stocks, but for now investors tend to believe that the acquisition of mass immunity can be accelerated.

    Today Top Movers

    AstraZeneca PLC ADR (AZN), a Drug Manufacturers company, soared about 2.38% ‎at $51.09 in pre-market trading today following its Covid-19 vaccine approval in the U.K.

    Guardion Health Sciences Inc (GHSI) share price jumped 7.029% to $0.41 during early morning ‎trading session on Wednesday following the declaration of appointment of Bret Scholtes, as its President and Chief Executive Officer.

    NXT-ID Inc (NXTD) stock ascended 9.16% at $1.43 in the pre-‎market trading today. 

    American Battery Metals Corp USD (ABML) gained over 1.43% at $1.42 in pre-market ‎trading on Wednesday.‎

    Top Upgrades & Downgrades

    AlphaValue turned bullish on AstraZeneca PLC ADR (AZN)‎, upgrading the ‎stock to “Add”.

    ‎Baird turned bullish on Caterpillar Inc. (NYSE: CAT), reiterating the stock at ‎‎“Outperform” but lifting the target from $206 to $220, representing potential ‎upside of 24.54% from Tuesday’s close.

    Daiwa turned bullish on Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)‎ , initiating the stock at ‎‎“Outperform” and assigning the target to $250, representing potential upside ‎of 7.07% from Tuesday’s close.

    Latest Insider Activity

    Lemonade Inc. (LMND) Chief Insurance Officer Peters John Sheldon announced the sale of shares taking place on Dec 28 at $118.49 for some 5,000 shares. The total came to more than $0.59 million.

    Pinterest Inc. (PINS) Chairman, President, CEO, Co-F Silbermann Benjamin sold on Dec 24 a total 105,000 shares at $71.55 on average. The insider’s sale generated proceeds of almost $7.51 million.

    Cellectar Biosciences Inc. (CLRB) Chief Business Officer Longcor Jarrod declared the purchase of shares taking place on Dec 28 at $1.35 for some 29,630 shares. The transaction amount was around $40001.

    TRACON Pharmaceuticals Inc. (TCON) 10% Owner Opaleye Management Inc. bought on Dec 22 a total 2,293,371 shares at $8.06 on average. The purchase cost the insider an estimated $4.0 million.

  • Here’s Why You Should Hold These 15 Biotech Stocks

    Here’s Why You Should Hold These 15 Biotech Stocks

    The biotechnology industry is considered to be an attractive industry for investors as the investors are always looking for safe and secure investments. This industry is a good option for investors as it is a strong and profitable industry. Companies in the biotechnology industry are continuously striving and exploring treatment for rare diseases. This industry has a significant contribution to the well-being of society. The biotechnology industry is constantly experiencing tech improvements and new scientific discoveries.

    Technology has always been at the heart of the biotechnology industry. New technological advancements are helpful for the biotechnology industry. This industry is anticipated to show a higher growth rate over the period of the next seven years. Globally, it is predicted that this industry will generate massive revenue in the coming years and it will also provide investment opportunities to investors who want to invest in the research and development of this industry.

    The following are the leading companies in the biotechnology industry. Let check how these companies are providing the best services to their clients:

    Sorrento Therapeutics Inc. (NASDAQ: SRNE)

    Sorrento Therapeutics Inc. (NASDAQ: SRNE) shares were trading down -10.49% at $9.30 at the time of writing on Friday. Sorrento Therapeutics Inc. (NASDAQ: SRNE) share price went from a low point around $1.45 to briefly over $19.39 in the past 52 weeks, though shares have since pulled back to $9.30. SRNE market cap has remained high, hitting $2.72B at the time of writing, giving it a price-to-sales ratio of more than 70.

    Sorrento Therapeutics Inc. (SRNE) has announced earlier that it has secured the receipt of clearance from a Brazilian regulatory agency to continue with a Phase 2 clinical trial of Abivertinib in mild, moderate, and severe COVID-19 patients. If we look at the recent analyst rating SRNE, H.C. Wainwright reiterated coverage on SRNE shares with a Buy rating.

    EyePoint Pharmaceuticals Inc. (NASDAQ: EYPT)

    EyePoint Pharmaceuticals Inc. (EYPT) last closed at $0.48, in a 52-week range of $0.46 to $2.69. EyePoint Pharmaceuticals Inc. (EYPT) revealed changes to its existing debt facility with CRG Servicing LLC (CRG). Under the terms of the amendment, CRG has waived the covenant associated with the Company’s net product revenue of DEXYCU and YUTIQ for the twelve-month period ending on December 31, 2020.

    Vaxart Inc. (NASDAQ: VXRT)

    Vaxart Inc. (VXRT) stock drop by -3.49% to $6.08. The most recent rating by H.C. Wainwright, on August 12, 2020, is at a Buy. The Schall Law Firm disclosed that the class-action lawsuit has been lodged against Vaxart, Inc. (VXRT)  for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

    Novan Inc. (NASDAQ: NOVN)

    Novan Inc. (NASDAQ: NOVN) shares headed falling, lower as much as -4.59%. The most recent rating by Piper Jaffray, on January 06, 2020, is at a Neutral. Novan Inc. (NOVN) revealed earlier that the positive in vitro results exhibited the potential efficacy of its NITRICIL™ platform technology as an antiviral against SARS-CoV-2, the virus that causes COVID-19.

    Akebia Therapeutics Inc. (NASDAQ: AKBA)

    Akebia Therapeutics Inc. (NASDAQ: AKBA) rose 3.42% after gaining more than $0.13 on Friday. Akebia Therapeutics Inc. (AKBA) revealed that it is scheduled to present data from its global Phase 3 programs of vadadustat for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis ) and not on dialysis at the American Society of Nephrology Kidney Week 2020 Reimagined (ASN Kidney Week) on October 22 – 25, 2020.

    Royalty Pharma plc (NASDAQ: RPRX)

    Royalty Pharma plc (RPRX) last closed at $41.81, in a 52-week range of $38.54 to $56.50. Analysts have a consensus price target of $52.67. Royalty Pharma plc (RPRX) disclosed today that it is scheduled to announce its third-quarter 2020 financial results on Wednesday, November 11, 2020, before the U.S. financial markets open.

    Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)

    Vertex Pharmaceuticals Incorporated (VRTX) stock soar by 1.30% to $218.08. The most recent rating by H.C. Wainwright, on July 31, 2020, is at a Buy. Vertex Pharmaceuticals Incorporated (VRTX) shared an update on its clinical programs targeting the small molecule correction of alpha-1 antitrypsin deficiency (AATD).

    iBio Inc. (AMEX: IBIO)

    iBio Inc. (AMEX: IBIO) Shares headed falling, lower as much as -1.44%. The most recent rating by Alliance Global Partners, on June 26, 2020, is at a Buy. iBio Inc. (IBIO) earlier revealed it has appointed Dr. Alexandra Kropotova to its Board of Directors, effective as of October 14, 2020. Dr. Kropotova has also been chosen as a member of iBio’s new Science & Technology Committee, which shall be chaired by Dr. Philip Russell.

    Onconova Therapeutics Inc. (NASDAQ: ONTX)

    Onconova Therapeutics Inc. (NASDAQ: ONTX) last closed at $0.29, in a 52-week range of $0.10 to $1.56. Onconova Therapeutics Inc. (ONTX) earlier disclosed that Dr. Steven M. Fruchtman, President and Chief Executive Officer, will present a company update during the 2020 BIO Investor Forum Digital event taking place October 13-15. Dr. Fruchtman and Avi Oler, Senior VP, Corporate Development, will be available for 1×1 meetings scheduled through the Bio Partnering system.

    Moderna Inc. (NASDAQ: MRNA)

    Moderna Inc. (NASDAQ: MRNA) Shares headed falling, lower as much as -2.17%. The most recent rating by SVB Leerink, on September 08, 2020, is at an Underperform. Moderna Inc. (MRNA) has earlier disclosed the initiation of a rolling submission to Health Canada for mRNA-1273. This initiation follows positive results from a preclinical viral challenge study of mRNA-1273 and the positive interim analysis of the Phase 1 study of mRNA-1273 in healthy adults and older adults.

    Selecta Biosciences Inc. (NASDAQ: SELB)

    Selecta Biosciences Inc. (NASDAQ: SELB) rose 18.01% after gaining more than $0.38 on Friday. Selecta Biosciences Inc. (SELB) has earlier announced an agreement with IGAN Biosciences, Inc. The agreement is the Research License and Option agreement signed to study Selecta’s ImmTOR™ immune tolerance platform in combination with IGAN’s immunoglobulin A (IgA) protease for the treatment of IgA Nephropathy (IgAN).

    Immunomedics Inc. (NASDAQ: IMMU)

    Immunomedics Inc. (NASDAQ: IMMU) stock soar by 0.08% to $87.56. The most recent rating by Barclays, on May 05, 2020, is at an Overweight. Immunomedics Inc. (IMMU) disclosed that the Office of Orphan Products Development of the U.S. Food and Drug Administration (FDA) has granted Trodelvy orphan status for the treatment of adult and pediatric patients with glioblastoma.

    Clovis Oncology Inc. (NASDAQ: CLVS)

    Clovis Oncology Inc. (NASDAQ: CLVS) fall -0.75% after losing more than -$0.05 on Friday. Clovis Oncology Inc. (CLVS) share price went from a low point around $2.93 to briefly over $17.37 in the past 52 weeks. It has moved up 102.56% from its 52-weeks low and moved down -65.83% from its 52-weeks high. CLVS market cap has remained high, hitting $532.72 million at the time of writing.

    Inovio Pharmaceuticals Inc. (NASDAQ: INO)

    Inovio Pharmaceuticals Inc. (NASDAQ: INO) stock drop by -2.95% to $11.85. The most recent rating by Maxim Group, on September 28, 2020, is at a Buy. Inovio Pharmaceuticals Inc. (INO) share price went from a low point around $2.09 to briefly over $33.79 in the past 52 weeks. It has moved up 456.84% from its 52-weeks low and moved down -65.56% from its 52-weeks high. INO market cap has remained high, hitting $2.05 Billion at the time of writing.

    MannKind Corporation (NASDAQ: MNKD)

    MannKind Corporation (NASDAQ: MNKD) last closed at $2.00, in a 52-week range of $0.80 to $2.48. MannKind Corporation (MNKD) has moved up 157.08% from its 52-weeks low and moved down -17.07% from its 52-weeks high. MNKD market cap has remained high, hitting $441.20 Million at the time of writing.